Expression and significance of miR‑24 and miR‑101 in patients with advanced gastric cancer

Abstract

Clinical significance of micro ribonucleic acid (miR)-24 and miR-101 were investigated by evaluating the expression of miR-24 and miR-101 in the tissues of patients with advanced gastric cancer. A total of 247 gastric cancer tissue specimens and 150 cancer-adjacent normal tissues (>5 cm away from the tumor) from patients with advanced gastric cancer who underwent surgical resection in the Surgical Oncology Department of Tianjin Union Medical Centre (Tianjin, China) from April 2013 to May 2016 were collected. The expression of miR-24 and miR-101 in gastric cancer and cancer-adjacent normal tissues were detected via reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and the correlation of the levels of miR-24 and miR-101 in gastric cancer tissues with their clinical and pathological features were explored. The expression level of miR-24 in gastric cancer tissues was significantly higher than that in cancer-adjacent normal tissues (t=10.26, p<0.01), while the expression level of miR-101 was significantly lower (t=13.940, p<0.01). The expression of miR-24 and miR-101 in gastric cancer was correlated with the pathological differentiation degree of the tumor, lymph node metastasis and depth of infiltration (p<0.05). The multivariate Cox regression analysis revealed that miR-24 and miR-101 were independent prognostic factors affecting the overall survival of patients (p<0.01). The results indicated that the expression of miR-24 is upregulated and that of miR-101 is downregulated in gastric cancer tissues. miR-24 and miR-101 may promote the occurrence, development, infiltration and metastasis of gastric cancer, and can be indicators for the prognosis of patients with gastric cancer.

MiR-24-3p and various cancers: From a meta-analysis view

“…Among these studies, several types of cancer include lung cancer (n = 3) [33][34][35], hepatocellular carcinoma (n = 2) [36,37], colorectal cancer (n = 2) [29,38], nasopharyngeal carcinoma (n = 2) [39,40], osteosarcoma (n = 1) [41], ALL (n = 1) [42], AML (n = 1) [42], advanced gastric cancer (n = 1) [28], esophageal cancer (n = 1) [43], head and neck squamous cell carcinoma (n = 1) [44]. As for OS, RFS and DFS, there were seven studies directly provide HRs and its 95% CI [28,29,[35][36][37][38][39]. In addition, the remaining eight studies only provided Kaplan-Meier curves [28,33,34,[40][41][42][43][44].…”

“…Previous studies showed that miR-24-3p was highly expressed in many carcinomas [26,27]. In addition, the evaluated expression of miR-24-3p was also found to be associated with cancer prognosis and tumor clinicopathological features but there were some opposite consequences [28,29]. Up to now, a number of studies have been investigate this molecule in many kinds of cancer, but most individual study have their own limits, for example, small sample size or obtaining controversial results, and so on.…”

Serum miR-101-3p combined with pepsinogen contributes to the early diagnosis of gastric cancer

“…The expression of miR-101 in GC tissues was significantly decreased compared with adjacent normal tissues [9][10][11]. Dong X et al have proved that miR-101 is an independent prognostic factor for the overall survival of GC patients that correlated with the pathological differentiation degree, lymph node metastasis and depth of infiltration [10]. Imamura T et al have confirmed that plasma miR-101 is a biomarker for GC that associated with the T factor, disease stage, peritoneal metastasis and the prognosis [12].…”

“…MiR-101 acts as a tumor suppressor in GC. The expression of miR-101 in GC tissues was significantly decreased compared with adjacent normal tissues [9][10][11]. Dong X et al have proved that miR-101 is an independent prognostic factor for the overall survival of GC patients that correlated with the pathological differentiation degree, lymph node metastasis and depth of infiltration [10].…”

“…. Dong X et al have proved that the expression of miR-101 in GC tissues is significantly lower than that in cancer-adjacent normal tissues, and miR-101 is an independent prognostic factor affecting the overall survival of GC patients [10]. Rossi T et al have shown that miR-101 is significantly down-regulated in 33 patients with intestinal GC [11].…”